Lei Shi
About Lei Shi
Lei Shi is a Director at Acrivon Therapeutics, Inc., with extensive experience in cancer genetics and drug development. He has held various academic and research positions, including roles at the Broad Institute of MIT and Harvard, Harvard Medical School, and Massachusetts General Hospital.
Current Role at Acrivon Therapeutics
Lei Shi serves as Director at Acrivon Therapeutics, Inc. since 2024. In this role, he is involved in overseeing projects that focus on drug development and biomarker research. His experience in the pharmaceutical industry supports his contributions to advancing therapeutic strategies aimed at improving patient outcomes.
Previous Experience at Acrivon Therapeutics
Prior to his current position, Lei Shi worked as Associate Director of Biomarker Development at Acrivon Therapeutics from 2022 to 2024. In this capacity, he played a significant role in the development and validation of biomarkers that are critical for the evaluation of therapeutic candidates.
Academic Background and Research Experience
Lei Shi holds a Doctor of Philosophy (PhD) in Biochemistry from UT Southwestern Medical Center, which he completed from 2008 to 2014. He also earned a Bachelor's degree in Biochemistry from Purdue University from 2006 to 2008. His academic journey laid the foundation for over fifteen years of training and research experience in cancer genetics and targeted therapeutics.
Work at Broad Institute and Harvard Medical School
From 2018 to 2022, Lei Shi was a Postdoctoral Research Fellow at the Broad Institute of MIT and Harvard. He also served as an Instructor in Medicine at Harvard Medical School and Massachusetts General Hospital from 2020 to 2022. His roles involved conducting research on biological mechanisms and drug candidates, contributing to the understanding of complex human diseases.
Research Contributions and Skills
Lei Shi has led projects that investigate basic biological mechanisms and pre-clinical studies of drug candidates. His skills include innovative thinking, problem-solving, and collaborative leadership. He aims to design novel therapeutic approaches that enhance human health, driven by a strong family background in pharmaceuticals.